Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   30925   clinical trials with a EudraCT protocol, of which   4800   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2009-011150-17
    Sponsor's Protocol Code Number:AMB112565
    National Competent Authority:Netherlands - Competent Authority
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2010-05-26
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedNetherlands - Competent Authority
    A.2EudraCT number2009-011150-17
    A.3Full title of the trial
    AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects with Pulmonary Arterial Hypertension
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Ambrisentan and Tadalafil Combination Therapy in Subjects with Pulmonary Arterial Hypertension
    A.3.2Name or abbreviated title of the trial where available
    AMBITION
    A.4.1Sponsor's protocol code numberAMB112565
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorGlaxoSmithKline R&D Ltd
    B.1.3.4CountryUnited Kingdom
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportGlaxoSmithKline Research & Development Ltd
    B.4.2CountryUnited Kingdom
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationGlaxoSmithKline Research & Development Ltd
    B.5.2Functional name of contact pointClinical Trials Helpdesk
    B.5.3 Address:
    B.5.3.1Street AddressIron Bridge Road, Stockley Park west
    B.5.3.2Town/ cityUxbridge, Middlesex
    B.5.3.3Post codeUnited Kingdom
    B.5.3.4CountryUnited Kingdom
    B.5.4Telephone number+442089904466na
    B.5.5Fax numbernananana
    B.5.6E-mailGSKClinicalSupportHD@gsk.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Volibris
    D.2.1.1.2Name of the Marketing Authorisation holderGlaxo Group Ltd
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/05/273
    D.3 Description of the IMP
    D.3.1Product nameambrisentan 5 mg film-coated tablets
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNAMBRISENTAN
    D.3.9.1CAS number 177036-94-1
    D.3.9.2Current sponsor codeGSK1325760
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Cialis
    D.2.1.1.2Name of the Marketing Authorisation holderEli Lilly Nederland B.V.
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nametadalafil 20 mg film-coated tablets
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTADALAFIL
    D.3.9.1CAS number 171596-29-5
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    D.8 Placebo: 2
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Pulmonary arterial hypotension
    E.1.1.1Medical condition in easily understood language
    Pulmonary arterial hypotension
    E.1.1.2Therapeutic area Diseases [C] - Virus Diseases [C02]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.1
    E.1.2Level PT
    E.1.2Classification code 10064911
    E.1.2Term Pulmonary arterial hypertension
    E.1.2System Organ Class 10038738 - Respiratory, thoracic and mediastinal disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To compare the two treatment strategies; first-line combination therapy (ambrisentan AND tadalafil) versus first-line monotherapy (ambrisentan OR tadalafil) in treatment naive subjects with PAH. This will be assessed by time to the first clinical failure event.
    E.2.2Secondary objectives of the trial
    To compare the change in other clinical measures of PAH after initiating first-line combination therapy or first-line monotherapy, in subjects with PAH.

    The safety and tolerability of first-line combination therapy will be compared to first-line monotherapy.

    In addition, the effect of ambrisentan on exercise capacity at both peak and trough plasma concentrations will be assessed in subjects with pulmonary arterial hypertension (PAH).
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Subjects eligible for enrolment in the study must meet all of the following criteria:
    Demographics
    1. Subject must be between 18 and 75 years of age, inclusive, at the Screening Visit
    2. Subject must weigh ≥40 kg at the Screening Visit
    PAH Diagnosis and Classification
    3. Subjects must have a diagnosis of PAH due to the following:
    a. idiopathic or heritable PAH
    b. PAH associated with:
    i. connective tissue disease (e.g., limited scleroderma, diffuse scleroderma,
    mixed CTD, systemic lupus erythematosus, or overlap syndrome)
    ii. drugs or toxins
    iii. HIV infection
    iv. congenital heart defects repaired greater than 1 year prior to screening (i.e., atrial septal defects, ventricular septal defects, and patent ductus arteriosus)
    NB: subjects with portopulmonary hypertension and PVOD are NOT eligible for the study
    NB: Subjects must not have 3 or more of the following left ventricular
    disease/dysfunction risk factors:
    i. Body Mass Index (BMI) ≥ 30
    ii. History of Essential Hypertension
    iii. Diabetes Mellitus – any type
    iv. Historical evidence of significant coronary disease established by any one of:
    • history of myocardial infarction
    • history of percutaneous intervention
    • angiographic evidence of CAD (>50% stenosis in at least one vessel), either by invasive angiography or by CT Angiography
    • positive stress test with imaging (either pharmacologic or with exercise)
    • previous coronary artery surgery
    • chronic stable angina
    4. Subject must have a current diagnosis of being in WHO Functional Class II or III.
    5. Subject with a diagnosis of HIV must have stable disease status. For this study, stable HIV status is defined as:
    i. No addition of medications for treatment of HIV for at least 8 weeks prior to screening
    ii. No active opportunistic infection during the Screening Period
    iii. No hospitalizations due to HIV for at least 4 weeks prior to screening
    6. Subject must meet all of the following haemodynamic criteria by means of a RHC prior to screening:
    i. mPAP of ≥25 mmHg
    ii. PVR ≥ 300 dynes/sec/cm5
    iii. PCWP or LVEDP of ≤12 mmHg if PVR ≥300 to <500 dyne⋅sec/cm5 , or PCWP/LVEDP ≤15 mmHg if PVR ≥500 dynes/sec/cm5
    (refer to section 4.2 for US specific text).
    7. Subject must meet all of the following pulmonary function tests completed no more
    than 24 weeks before the Screening visit:
    i. Total lung capacity (TLC) ≥60% of predicted normal and
    ii. Forced expiratory volume in one second (FEV1) ≥55% of predicted
    normal
    Subjects are required to have a documented negative V/Q scan or pulmonary arteriogram confirming the absence of CTEPH prior to screening.
    8. Subject must walk a distance of ≥125m and ≤500m at the screening visit. In addition the screening and baseline 6MWD tests must not vary by greater than 10% (see Section 6.2.2.1 for further details)
    9. Subject, with or without supplemental oxygen, must have a resting arterial oxygen saturation (SaO2) ≥88% as measured by pulse oximetry at the Screening Visit.
    Exercise Programmes
    10. Subject has not enrolled in an exercise training program for pulmonary rehabilitation within 12 weeks prior to the Screening Visit and must agree not to enroll in an exercise training program for pulmonary rehabilitation during the Screening Period and the first 24 weeks of the study. Subjects enrolled in an exercise program for pulmonary rehabilitation 12 weeks prior to screening may enter the study if they agree to maintain their current level of rehabilitation for the first 24 weeks of the study.
    General
    11. Female subject of childbearing potential, if sexually active, must agree to use 2 reliable methods of contraception from the Screening Visit until study completion and for at least 30 days following the last dose of Investigational Product (reliable methods of contraception are described in Appendix 1). Subjects who have had a Copper T 380A IUD or LNg 20 IUD inserted are not required to use additional methods of contraception
    12. Subject must agree not to participate in a clinical study involving another investigational drug or device throughout this study
    13. Subject must be competent to understand the information given in the Institutional
    Review Board (IRB) or Independent Ethics Committee (IEC) approved ICF and must sign the form prior to the initiation of any study procedures
    Specific information regarding warnings, precautions, contraindications, adverse events, and other pertinent information on the investigational product that may impact subject eligibility is provided in the IB and product label.
    French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.
    E.4Principal exclusion criteria
    Subjects meeting any of the following criteria must not be enrolled in the study (please
    note that screening visit laboratory tests may be performed by local or central laboratory):
    PAH Treatments
    1. Subject received previous PAH therapy (PDE5i, ERA, chronic prostanoid*) within 4
    weeks prior to the screening visit
    *Chronic prostanoid use is considered >7 days of treatment
    2. Subject received ERA treatment (e.g., bosentan or sitaxentan) or PDE5i treatment
    (e.g. Sildenafil) at any time AND discontinued due to tolerance issues other than those associated with liver function abnormalities
    3. Subjects who have previously discontinued ambrisentan or tadalafil in either another clinical study or commercial product (Volibris/Letairis or Adcirca) for safety or tolerability reasons.
    4. Subject has a known hypersensitivity to the Investigational Products, the metabolites,
    or formulation excipients
    Other Therapies
    5. Subject receiving intravenous inotropes within 2 weeks prior to the Screening Visit
    (e.g. dopamine, dobutamine)
    6. Subject is receiving treatment with a potent inhibitor of CYP3A4 (e.g. protease
    inhibitors, systemic ketoconazole, or systemic itraconazole)
    7. Subject is receiving treatment with a potent inducer of CYP3A4 (e.g. rifampicin)
    8. Subject is receiving treatment with cyclosporine A (except ophthalmic formulation)
    9. Subjects receiving Calcium Channel Blockers or HMG-CoA reductase inhibitors
    (i.e., statins) on an unstable dose 4 weeks prior to the Screening Visit (to be eligible
    subjects must not have changed their dose <4 weeks prior to the screening visit)
    10. Subject has a history of angina pectoris that was treated with long or short-acting
    nitrates <12 weeks of screening or nitrate use for any other condition within 48 hours
    of screening
    11. Subject has a serum ALT or AST lab value that is > 2xULN at the Screening Visit
    12. Subject has serum bilirubin lab value that is >1.5xULN at the screening visit
    13. Subject has severe renal impairment (creatinine clearance <30 mL/min) at the
    Screening Visit
    Medical History/Current Medical Conditions
    Liver
    14. Subject has severe hepatic impairment (Child-Pugh class C with or without cirrhosis)
    at the Screening Visit
    Haematology and bleeding disorders
    15. Subject has clinically significant anaemia in the opinion of the investigator
    16. Subjects with bleeding disorders or significant active peptic ulceration in the opinion
    of the investigator
    Cardiovascular
    17. Subject has uncontrolled hypertension (≥180/110 mmHg) at screening
    18. Subject has severe hypotension (<90/50 mmHg) at screening
    19. Subject has had an acute myocardial infarction within the last 90 days prior to
    screening
    20. Subject has, in the opinion of the investigator, clinically significant aortic or mitral valve disease; pericardial constriction; restrictive or congestive cardiomyopathy; lifethreatening cardiac arrhythmias; significant left ventricular dysfunction; left
    ventricular outflow obstruction; symptomatic coronary artery disease; autonomic
    hypotension; fluid depletion.
    Ophthalmic
    21. Subject has a past medical history of NAION
    22. Subject has a hereditary degenerative retinal disorder (e.g. retinitis pigmentosa)
    General Medical Conditions
    23. Subject has clinically significant fluid retention in the opinion of the investigator
    24. Subject with cardiovascular, liver, renal, haematologic, gastrointestinal,
    immunologic, endocrine, metabolic, or central nervous system disease that, in the
    opinion of the Investigator, may adversely affect the safety of the subject and/or
    efficacy of the investigational product or severely limit the lifespan of the subject
    other than the condition being studied
    25. Subject has a history of malignancies within the past 5 years, except for a subject
    with localized, non-metastatic basal cell carcinoma of the skin, in situ carcinoma of
    the cervix, or prostate cancer who is not currently or expected, during the study, to
    undergo radiation therapy, chemotherapy, and/or surgical intervention, or to initiate
    hormonal treatment
    General Criteria
    26. Female subject who is pregnant or breastfeeding
    27. Subject has demonstrated noncompliance with previous medical regimens
    28. Subject has a recent (within 1 year) history of abusing alcohol or illicit drugs
    29. Subject has participated in a clinical study involving another investigational drug or
    device within 4 weeks before the Screening Visit
    Subjects who fail inclusion/exclusion criteria may be re-screened once.
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy endpoint is the time to the first clinical failure event of PAH. Time to clinical failure is defined as the time from randomisation to the first occurrence of:
    • Death (all-cause)
    • Hospitalization for worsening PAH (adjudicated)
    i. Any hospitalization for worsening PAH
    ii. Lung or heart/lung transplant
    iii. Atrial septostomy
    iv. Initiation of parenteral prostanoid therapy
    • Disease progression (adjudicated)
    i. >15% decrease from baseline in 6MWD combined with WHO class III or IV symptoms (at two consecutive post-baseline clinic visits separated by ≥14 days)
    • Unsatisfactory long-term clinical response (adjudicated, all criteria required)
    i. Receiving randomised treatment for at least 6 months
    ii. A decrease from baseline in 6MWD at two consecutive post-baseline clinic visits separated by ≥14 days
    iii. Sustained WHO class III symptoms for ≥6 months (WHO class III symptoms assessed at two clinic visits separated by ≥6 months)


    Time to clinical worsening (death, hospitalization for worsening PAH, or disease progression) and long-term survival (time to death) will be examined as supportive analyses of the primary endpoint.
    E.5.1.1Timepoint(s) of evaluation of this end point
    during the trial
    E.5.2Secondary end point(s)
    • Change from baseline 6MWD measured at week 24
    • Percentage of subjects with satisfactory clinical response measured at week 24, defined as:
    -10% improvement in 6MWD compared to baseline
    - Improvement to or maintenance of WHO class I or II symptoms
    - No events of clinical worsening prior to or at the week 24 visit
    • Change from baseline measured at week 24 in N-terminal pro-B-type natriuretic peptide (NT-proBNP)
    • Change from baseline measured at week 24 in WHO Functional Class
    • Change from baseline measured at week 24 in BDI immediately following exercise
    E.5.2.1Timepoint(s) of evaluation of this end point
    week 24
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) Yes
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA65
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Japan
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The AMBITION study is an event driven study. At the time that 105 adjudicated primary endpoint events have occurred, i.e. 105 mITT subjects with an event, all subjects will be notified to return for a Final Assessment Visit (FAV) within 28 days or their week 24 visit, whichever is later.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months1
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months1
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 270
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 130
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception For clinical trials recorded in the database before the 10th March 2011 this question read: "Women of childbearing potential" and did not include the words "not using contraception". An answer of yes could have included women of child bearing potential whether or not they would be using contraception. The answer should therefore be understood in that context. This trial was recorded in the database on 2010-05-26. Yes
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state23
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 250
    F.4.2.2In the whole clinical trial 545
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Following the first database lock, subjects will be requested to return for an end of study visit where they will have their final assessment done and be unblinded.
    Investigator should then treat the subjects according to best standard of care available to the investigator. Subjects will be followed for 30 days post their last dose of study medication. The sponsor will no longer supply ambrisentan or tadalafil after the end of the study.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2010-07-02
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2010-08-26
    P. End of Trial
    P.End of Trial StatusOngoing
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-Sat Aug 19 23:36:44 BST 2017 | 30 Churchill Place, Canary Wharf, London E14 5EU
    Legal notice
    EMA HMA